![conference banner](/images/conference-banner.jpeg)
Abstract
The development of atherosclerotic lesions in the artery wall is a complex process involving the endothelium, lipid engorged macrophages (foam cells) and smooth muscle cells. In recent years it has become clear that chylomicron remnants, the lipoproteins which carry lipids of dietary origin in the blood, are strongly atherogenic, and there is increasing evidence to indicate that this is due to direct interaction of the remnant particles with cells of the artery wall. Chylomicron remnants have been demonstrated to inhibit endothelium dependent vasorelaxation and to activate signal transduction pathways associated with inflammation in cultured endothelial cells. They have also been shown to be taken up by smooth muscle cells and macrophages, and to cause the extensive lipid accumulation associated with foam cell formation, as well as influencing the expression of key genes regulating macrophage lipid uptake and metabolism. Furthermore, oxidative modification of the remnant particles is not required for many of these effects. Chylomicron remnants, therefore, have mutiple direct effects on three major cell types of the arterial wall which are likely to promote the development of atherosclerotic lesions. These effects may be modulated by various lipids carried by the particles, including the type of fat (saturated or unsaturated or oxidised fat), micronutrients such as vitamins and carotenoids which have antioxidant properties, and orally administered lipophilic drugs. Delayed clearance of chylomicron remnants from the blood occurs in a number of dyslipidemias associated with premature atherosclerosis development, and the potentially atherogenic effects of the particles would clearly be enhanced in these circumstances. Thus, elucidation of the mechanisms involved will aid in the identification of new drug targets which may be particularly useful for these conditions.
Keywords: chylomicron remnants, dietary lipids, endothelium, smooth muscle cells, macrophages, lipoprotein oxidation, antioxidants, atheroscerosis
Current Pharmaceutical Design
Title: Direct Interaction of Dietary Lipids Carried in Chylomicron Remnants with Cells of the Artery Wall: Implications for Atherosclerosis Development
Volume: 11 Issue: 28
Author(s): K. M. Botham, E. Bravo, J. Elliott and C. P.D. Wheeler-Jones
Affiliation:
Keywords: chylomicron remnants, dietary lipids, endothelium, smooth muscle cells, macrophages, lipoprotein oxidation, antioxidants, atheroscerosis
Abstract: The development of atherosclerotic lesions in the artery wall is a complex process involving the endothelium, lipid engorged macrophages (foam cells) and smooth muscle cells. In recent years it has become clear that chylomicron remnants, the lipoproteins which carry lipids of dietary origin in the blood, are strongly atherogenic, and there is increasing evidence to indicate that this is due to direct interaction of the remnant particles with cells of the artery wall. Chylomicron remnants have been demonstrated to inhibit endothelium dependent vasorelaxation and to activate signal transduction pathways associated with inflammation in cultured endothelial cells. They have also been shown to be taken up by smooth muscle cells and macrophages, and to cause the extensive lipid accumulation associated with foam cell formation, as well as influencing the expression of key genes regulating macrophage lipid uptake and metabolism. Furthermore, oxidative modification of the remnant particles is not required for many of these effects. Chylomicron remnants, therefore, have mutiple direct effects on three major cell types of the arterial wall which are likely to promote the development of atherosclerotic lesions. These effects may be modulated by various lipids carried by the particles, including the type of fat (saturated or unsaturated or oxidised fat), micronutrients such as vitamins and carotenoids which have antioxidant properties, and orally administered lipophilic drugs. Delayed clearance of chylomicron remnants from the blood occurs in a number of dyslipidemias associated with premature atherosclerosis development, and the potentially atherogenic effects of the particles would clearly be enhanced in these circumstances. Thus, elucidation of the mechanisms involved will aid in the identification of new drug targets which may be particularly useful for these conditions.
Export Options
About this article
Cite this article as:
Botham M. K., Bravo E., Elliott J. and Wheeler-Jones P.D. C., Direct Interaction of Dietary Lipids Carried in Chylomicron Remnants with Cells of the Artery Wall: Implications for Atherosclerosis Development, Current Pharmaceutical Design 2005; 11 (28) . https://dx.doi.org/10.2174/138161205774580732
DOI https://dx.doi.org/10.2174/138161205774580732 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Application of Proteomics in Cardiovascular Research
Current Proteomics Neutrophil Cell Count is Related to Hypertension in Workers: A Cross- Sectional Study
Vascular Disease Prevention (Discontinued) Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology Prion Protein Functions and Dysfunction in Prion Diseases
Current Medicinal Chemistry Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Randomized, Placebo Controlled Study of the Effects of Etoricoxib on Markers of Inflammation, Pain and Muscle Force After Eccentric Exercise
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research Pharmacogenetics of the Metabolic Disturbances and Atherosclerosis Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Pharmaceutical Design Targeting the SH2 Domain-Containing Inositol Phosphatase (SHIP) for Therapy
Current Enzyme Inhibition Computational Biological Analysis Reveals a Role for Nitric Oxide Synthase and Adiponectin in the Pathobiology of Insulin Resistance Syndrome and Coronary Artery Disease
Current Nutrition & Food Science Regulation of Intracellular Cardiomyocyte Calcium Stores by Peptides: A New Approach to Cardiac Protection
Current Medicinal Chemistry Withdrawal Notice: Reconnoitering the Role of Endothelin in Obesity
Current Pharmaceutical Design Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry Clinical Significance of the New Cardiovascular Risk Markers in Diabetes Mellitus
Current Diabetes Reviews Differential Impact of Biologic Therapy on Heart Function Biomarkers in Rheumatoid Arthritis Patients: Observational Study on Etanercept, Adalimumab, and Tocilizumab
Current Pharmaceutical Design Efficacy and Cardiovascular Safety of Metformin
Current Drug Safety Disease Modifying Osteoarthritis Drugs: Facing Development Challenges and Choosing Molecular Targets
Current Drug Targets Therapeutic Strategies in the Treatment of Diabetic Nephropathy - a Translational Medicine Approach
Current Medicinal Chemistry